Identification of novel germline polymorphisms governing capecitabine sensitivity

Cancer

Volumn 118, Issue 16, 2012, Pages 4063-4073

  O'Donnell, Peter H ^a   Stark, Amy L ^a   Gamazon, Eric R ^a   Wheeler, Heather E ^a   McIlwee, Bridget E ^a   Gorsic, Lidija ^a   Im, Hae Kyung ^a   Huang, R Stephanie ^a   Cox, Nancy J ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

capecitabine; genome wide; meta analysis; pharmacogenomics; susceptibility

Indexed keywords

5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE REDUCTASE; CAPECITABINE; FLUOROURACIL; FOLIC ACID; METHIONINE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADCY2 GENE; ARTICLE; CAUCASIAN; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MTRR GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMARCAD1 GENE; STATISTICAL ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE;

EID: 84864661973     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26737     Document Type: Article

References (44)

1. Efferth T, Volm M,. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Therapeut. 2005; 107: 155-176.
2. Evans WE, Relling MV,. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999; 286: 487-491.
3. Cassidy J, Saltz L, Twelves C, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011; 22: 2604-2609.
4. Walko CM, Lindley C,. Capecitabine: a review. Clin Ther. 2005; 27: 23-44.
5. Aprile G, Mazzer M, Moroso S, Puglisi F,. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs. 2009; 20: 217-229.
6. Biganzoli L, Martin M, Twelves C,. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002; 7 (suppl 6): 29-35.
7. Clemons M, Joy AA, Abdulnabi R, et al. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Breast Cancer Res Treat. 2010; 124: 177-186.
8. Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007; 104: 9758-9763.
9. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005; 437: 1299-1320.
10. Hartford CM, Duan S, Delaney SM, et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009; 113: 2145-2153.
11. Huang RS, Duan S, Kistner EO, et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008; 68: 3161-3168.
12. Bleibel WK, Duan S, Huang RS, et al. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009; 125: 173-180.
13. O'Donnell PH, Gamazon E, Zhang W, et al. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants Pharmacogenet Genomics. 2010; 20: 327-337.
14. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME,. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics. 2009; 3: 128-142.
15. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME,. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther. 2008; 7: 3038-3046.
16. Welsh M, Mangravite L, Medina MW, et al. Pharmacogenomic discovery using cell-based models. Pharmacol Rev. 2009; 61: 413-429.
17. Ziliak D, O'Donnell PH, Im HK, et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011; 157: 265-272.
18. O'Donnell PH, Dolan ME,. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009; 15: 4806-4814.
19. Zhang W, Duan S, Kistner EO, et al. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet. 2008; 82: 631-640.
20. Stark AL, Zhang W, Mi S, et al. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010; 10: 505-512.
21. Stark AL, Zhang W, Zhou T, et al. Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010; 87: 829-833.
22. Browning BL, Browning SR,. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet. 2009; 84: 210-223.
23. Abecasis GR, Cookson WO, Cardon LR,. Pedigree tests of transmission disequilibrium. Eur J Hum Genet. 2000; 8: 545-551.
24. Price AL, Tandon A, Patterson N, et al. Sensitive detection of chromosomal segments of distinct ancestry in admixed populations [serial online]. PLoS Genet. 2009; 5: e1000519.
25. Devlin B, Roeder K,. Genomic control for association studies. Biometrics. 1999; 55: 997-1004.
26. Willer CJ, Li Y, Abecasis GR,. Metal: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010; 26: 2190-2191.
27. Torgerson DG, Boyko AR, Hernandez RD, et al. Evolutionary processes acting on candidate cis-regulatory regions in humans inferred from patterns of polymorphism and divergence [serial online]. PLoS Genet. 2009; 5: e1000592.
28. Wettergren Y, Odin E, Carlsson G, Gustavsson B,. MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4a hypermethylation in mucosa of patients with colorectal cancer. Mol Med. 2010; 16: 425-432.
29. de Bono JS, Twelves CJ,. The oral fluorinated pyrimidines. Invest New Drugs. 2001; 19: 41-59.
30. Johnson RC, Nelson GW, Troyer JL, et al. Accounting for multiple comparisons in a genome-wide association study (GWAS) [serial online]. BMC Genomics. 2010; 11: 724.
31. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007; 81: 427-437.
32. Pentheroudakis G, Twelves C,. Capecitabine (Xeloda): from the laboratory to the patient's home. Clin Colorectal Cancer. 2002; 2: 16-23.
33. Zhang X, Diasio RB,. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics. 2007; 8: 257-265.
34. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J,. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep. 2007; 17: 325-328.
35. Etienne-Grimaldi MC, Francoual M, Formento JL, Milano G,. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics. 2007; 8: 1561-1566.
36. Pardini B, Kumar R, Naccarati A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011; 72: 162-163.
37. Okazaki N, Ikeda S, Ohara R, et al. The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of TSS. J Mol Biol. 2008; 382: 257-265.
38. Cetin E, Cengiz B, Gunduz E, et al. Deletion mapping of chromosome 4q22-35 and identification of 4 frequently deleted regions in head and neck cancers. Neoplasma. 2008; 55: 299-304.
39. Adra CN, Donato JL, Badovinac R, et al. Smarcad1, a novel human helicase family-defining member associated with genetic instability: cloning, expression, and mapping to 4q22-q23, a band rich in breakpoints and deletion mutants involved in several human diseases. Genomics. 2000; 69: 162-173.
40. Pander J, Wessels JA, Gelderblom H, van der Straaten T, Punt CJ, Guchelaar HJ,. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol. 2011; 22: 1147-1153.
41. Largillier R, Etienne-Grimaldi MC, Formento JL, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res. 2006; 12: 5496-5502.
42. Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse human populations. Nature. 2010; 467: 52-58.
43. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449: 851-861.
44. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008; 9: 356-369.